98%
921
2 minutes
20
Brain metastases are a major cause of melanoma-related mortality and morbidity. We undertook whole-exome sequencing of 50 tumours from patients undergoing surgical resection of brain metastases presenting as the first site of visceral disease spread and validated our findings in an independent dataset of 18 patients. Brain metastases had a similar driver mutational landscape to cutaneous melanomas in TCGA. However, KRAS was the most significantly enriched driver gene, with 4/50 (8%) of brain metastases harbouring non-synonymous mutations. Hotspot KRAS mutations were mutually exclusive from BRAF, NRAS and HRAS mutations and were associated with a reduced overall survival from the resection of brain metastases (HR 10.01, p = 0.001). Mutations in KRAS were clonal and concordant with extracranial disease, suggesting that these mutations are likely present within the primary. Our analyses suggest that KRAS mutations could help identify patients with primary melanoma at higher risk of brain metastases who may benefit from more intensive, protracted surveillance.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782512 | PMC |
http://dx.doi.org/10.1038/s41416-020-01090-2 | DOI Listing |
Drug Dev Res
September 2025
R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India.
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with "epidermal growth factor receptor (EGFR)" mutations playing a pivotal role in tumor progression and carcinogenesis. "Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)," such as Osimertinib, have significantly improved treatment outcomes by overcoming resistance mechanisms like the T790M mutation. However, Osimertinib's clinical application is limited by cardiotoxicity concerns, necessitating safer alternatives.
View Article and Find Full Text PDFClin Transl Radiat Oncol
November 2025
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Background: Hypofractionated stereotactic radiotherapy (fSRT) is increasingly used for brain metastases (BMs) from non-small cell lung cancer (NSCLC). However, relevant data concerning treatment outcomes of fSRT and clinical utility of re-irradiation using fSRT (re-fSRT) remain scarce.
Methods: Consecutive NSCLC patients with fSRT-treated BMs from May 2018 to May 2022 were included.
Cureus
August 2025
Department of Radiology, Aichi Medical University, Nagakute, JPN.
Background This study was conducted to examine the effects of moving the isocenter (IC) position from the lesion to the center of the brain on stereotactic radiosurgery (SRS) planning with volumetric-modulated arcs (VMA) using the High-Definition Dynamic Radiosurgery (HDRS) platform, a combination of the Agility multileaf collimator (MLC) (Elekta AB, Stockholm, Sweden) and the Monaco planning system (Elekta AB), for single brain metastases (BMs). Methodology The study subject included 36 clinical BMs with the gross tumor volume (GTV) ranging from 0.04 to 48.
View Article and Find Full Text PDFCureus
August 2025
Department of Radiology, Aichi Medical University, Nagakute, JPN.
Purpose This planning study aimed to clarify the significance of inverse planning with variable dose rate (VDR) and the segment shape optimization (SSO) in the quality and efficiency of dynamic conformal arcs (DCA) using the high-definition dynamic radiosurgery (HDRS) platform for stereotactic radiosurgery (SRS) of single brain metastases (BMs). Materials and methods Twenty clinical BMs were included, with the gross tumor volume (GTV) ranging from 0.33 cc to 48.
View Article and Find Full Text PDFFront Immunol
September 2025
Department of Radiation Oncology, Jiangxi Cancer Hospital and Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China.
We present a case of a 68-year-old male with advanced non-small cell lung cancer (NSCLC), PD-L1 negative and driver gene negative, who exhibited a significant abscopal effect following radiotherapy combined with systemic immunotherapy (sintilizumab) and chemotherapy. The patient achieved complete remission (CR) of intracranial metastases without cranial irradiation, suggesting a systemic immune response triggered by the combination of radiotherapy and immunotherapy. This case highlights the potential of radiotherapy combined with immuno-chemotherapy to induce abscopal effects, even in PD-L1 negative patients, and underscores the importance of further investigation into this therapeutic strategy.
View Article and Find Full Text PDF